87 related articles for article (PubMed ID: 8854230)
1. Factorial dose-response studies using frequency and magnitude of dose.
Hafner KB; Ruberg SJ
J Biopharm Stat; 1996 Jul; 6(3):253-62. PubMed ID: 8854230
[TBL] [Abstract][Full Text] [Related]
2. Dose response studies. II. Analysis and interpretation.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):15-42. PubMed ID: 7613559
[TBL] [Abstract][Full Text] [Related]
3. Dose response studies. I. Some design considerations.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):1-14. PubMed ID: 7613556
[TBL] [Abstract][Full Text] [Related]
4. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
5. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
Bretz F; Maurer W; Hommel G
Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.
Beitz J; Gnecco C; Justice R
J Natl Cancer Inst Monogr; 1996; (20):7-9. PubMed ID: 8750460
[TBL] [Abstract][Full Text] [Related]
8. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
Quan H; Luo X; Capizzi T
Stat Med; 2005 Jul; 24(14):2151-70. PubMed ID: 15909290
[TBL] [Abstract][Full Text] [Related]
9. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
10. [Interim analyses].
Kramar A; Paoletti X
Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
[TBL] [Abstract][Full Text] [Related]
11. Identifying effective and/or safe doses by stepwise confidence intervals for ratios.
Bretz F; Hothorn LA; Hsu JC
Stat Med; 2003 Mar; 22(6):847-58. PubMed ID: 12627404
[TBL] [Abstract][Full Text] [Related]
12. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
13. Bayesian design and analysis of two x two factorial clinical trials.
Simon R; Freedman LS
Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445
[TBL] [Abstract][Full Text] [Related]
14. An improved method of evaluating drug effect in a multiple dose clinical trial.
Shen L
Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
[TBL] [Abstract][Full Text] [Related]
15. Concurrent versus sequential radiotherapy and tamoxifen in breast cancer - The CONSET trial is launched.
Munshi A; Gupta D
Acta Oncol; 2011 Jan; 50(1):154-5. PubMed ID: 20843175
[No Abstract] [Full Text] [Related]
16. Patterns of treatment effects in subsets of patients in clinical trials.
Bonetti M; Gelber RD
Biostatistics; 2004 Jul; 5(3):465-81. PubMed ID: 15208206
[TBL] [Abstract][Full Text] [Related]
17. Statistical methods for active extension trials.
Hu Z; Follmann D
Stat Med; 2007 May; 26(12):2433-48. PubMed ID: 17066400
[TBL] [Abstract][Full Text] [Related]
18. Design, analysis and presentation of factorial randomised controlled trials.
Montgomery AA; Peters TJ; Little P
BMC Med Res Methodol; 2003 Nov; 3():26. PubMed ID: 14633287
[TBL] [Abstract][Full Text] [Related]
19. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.
Lienhardt C; Davies G
Int J Tuberc Lung Dis; 2010 May; 14(5):528-37. PubMed ID: 20392344
[TBL] [Abstract][Full Text] [Related]
20. Designs for efficient clinical trials.
Simon R
Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
